Early intensive diabetes therapy preserves beta-cell function

July 6, 2012
Early intensive diabetes therapy preserves β-cell function
Early, intensive therapy for type 2 diabetes with either insulin plus metformin or triple oral therapy preserves β-cell function for at least 3.5 years, according to a study published in the July issue of Diabetes Care.

(HealthDay) -- Early, intensive therapy for type 2 diabetes with either insulin plus metformin or triple oral therapy preserves β-cell function for at least 3.5 years, according to a study published in the July issue of Diabetes Care.

Lindsay B. Harrison, M.D., of the University of Texas Southwestern Medical Center in Dallas, and colleagues conducted a randomized trial involving 58 patients with treatment-naive, newly diagnosed . Participants were treated for three months with and and were then randomly allocated to continue with insulin plus metformin or to receive triple oral therapy with metformin, glyburide, and pioglitazone. A mixed meal challenge test was used to assess β-cell function at randomization and six, 12, 18, 30, and 42 months.

After 3.5 years the researchers found that 83 percent of insulin plus metformin-treated patients and 72 percent of triple oral therapy patients completed the study, with good compliance noted in both groups. At 3.5 years after diagnosis, β-cell function was preserved between the groups, with no significant change from baseline or between-group difference (end of study hemoglobin A1c, 6.35 percent for insulin plus metformin versus 6.59 percent for triple oral therapy). In both groups there was an increase in weight, with no significant difference between the groups. Hypoglycemic episodes decreased over time for both groups and were not significantly different.

"Intensive insulin therapy at the time of diagnosis of type 2 followed by either an insulin-based regimen or multiple oral hypoglycemic agents preserves both glycemic control and β-cell function for at least 3.5 years with no significant difference in the adverse-effect profile," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Novo Nordisk, which funded the study.

Explore further: Study shows treating diabetes early, intensively is best strategy

More information: Abstract
Full Text

Related Stories

Study shows treating diabetes early, intensively is best strategy

June 28, 2012
Intensive early treatment of type 2 diabetes slows down progression of the disease by preserving the body's insulin-producing capacity, a UT Southwestern study has shown.

Patients with Type 2 diabetes may not benefit from oral medication as well as insulin

April 20, 2012
Patients suffering from type 2 diabetes may not benefit from taking both an oral glucose lowering drug (metformin) and insulin instead of insulin alone, a study published on bmj.com claims.

Researchers test a drug-exercise program designed to prevent type 2 diabetes

December 6, 2011
(Medical Xpress) -- Kinesiology researcher Barry Braun of the University of Massachusetts Amherst and colleagues recently reported unexpected results of a study suggesting that exercise and one of the most commonly prescribed ...

Dapagliflozin aids glycemic control in type 2 diabetes

March 20, 2012
(HealthDay) -- For patients with inadequately controlled type 2 diabetes, treatment with dapagliflozin is associated with improved glycemic control, stabilized insulin dosing, and weight reductions, according to research ...

Recommended for you

Getting fat to 'talk' again could lower blood glucose and weight

August 22, 2017
Diabetes is a tough disease to manage. Oral medications, insulin shots, close monitoring of blood sugar, dietary changes and exercise can all factor into a person's treatment regimen. Now researchers are exploring a novel, ...

Biochemical 'fingerprints' reveal diabetes progression

August 21, 2017
Researchers from Umeå University in Sweden describe a new method to study biochemical changes that occur in the pancreas during the development of diabetes. The method, recently published in Scientific Reports, is based ...

In a nutshell: Walnuts activate brain region involved in appetite control

August 17, 2017
Packed with nutrients linked to better health, walnuts are also thought to discourage overeating by promoting feelings of fullness. Now, in a new brain imaging study, researchers at Beth Israel Deaconess Medical Center (BIDMC) ...

Smart mat detects early warning signs of foot ulcers

August 16, 2017
While completing his residency in anesthesiology at Massachusetts General Hospital in the mid-2000s, Jon Bloom saw his fair share of foot amputations among patients with diabetes. The culprit: infected foot ulcers.

The best place to treat type 1 diabetes might be just under your skin

August 14, 2017
A group of U of T researchers have demonstrated that the space under our skin might be an optimal location to treat type 1 diabetes (T1D).

New measure of insulin-making cells could gauge diabetes progression, treatment

August 10, 2017
Researchers at the University of Wisconsin-Madison have developed a new measurement for the volume and activity of beta cells, the source of the sugar-regulating hormone insulin.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.